Jiachuan Xiong1, Ting He1, Min Wang2, Ling Nie1, Ying Zhang1, Yiqin Wang1, Yunjian Huang1, Bing Feng1, Jingbo Zhang1, Jinghong Zhao3. 1. Department of Nephrology, Institute of Nephrology of Chongqing and Kidney Center of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People's Republic of China. 2. Department of Otorhinolaryngology and Head-Neck Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People's Republic of China. 3. Department of Nephrology, Institute of Nephrology of Chongqing and Kidney Center of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People's Republic of China. zhaojh@tmmu.edu.cn.
Abstract
BACKGROUND: Previous studies reported that magnesium deficiency was associated with vascular calcifications, atherosclerosis and cardiovascular disease, which might play an independent pathogenic role in chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients. However, the results of these studies were somewhat underpowered and inconclusive. METHODS: Literature was identified by searching PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL). We included studies that investigated the association between serum magnesium with mortality risk in CKD and ESRD patients. Unadjusted and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs) were pooled. RESULTS: Twenty studies involving 200,934 participants were included, and the results showed that there was a strong association between hypomagnesemia and the risk of all-cause mortality in patients with CKD and ESRD (HR 1.32; 95% CI 1.19-1.47; p < 0.00001) (hypomagnesemia vs. normal magnesium or hypermagnesemia) after multivariable adjusted. On the contrary, hypermagnesemia was inversely associated with all-cause mortality in patients with CKD and ESRD (HR 0.86; 95% CI 0.79-0.94; p = 0.001) (per unit increase). Moreover, a significant association between hypermagnesemia and decreased risk of cardiovascular mortality was observed (HR 0.71; 95% CI 053-0.97, p = 0.03) in the adjusted model. In addition, subgroup analysis found that hypomagnesemia was strongly associated with increased all-cause mortality in hemodialysis patients (HR 1.29; 95% CI 1.12-1.50; p = 0.0005) (hypomagnesemia vs. normal magnesium or hypermagnesemia). CONCLUSIONS: Our results indicate that hypomagnesemia is significantly associated with cardiovascular and all-cause mortality in patients with CKD and ESRD. Further studies evaluating benefits of magnesium correction in CKD and dialysis patients with hypomagnesemia should be performed.
BACKGROUND: Previous studies reported that magnesium deficiency was associated with vascular calcifications, atherosclerosis and cardiovascular disease, which might play an independent pathogenic role in chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients. However, the results of these studies were somewhat underpowered and inconclusive. METHODS: Literature was identified by searching PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL). We included studies that investigated the association between serum magnesium with mortality risk in CKD and ESRDpatients. Unadjusted and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs) were pooled. RESULTS: Twenty studies involving 200,934 participants were included, and the results showed that there was a strong association between hypomagnesemia and the risk of all-cause mortality in patients with CKD and ESRD (HR 1.32; 95% CI 1.19-1.47; p < 0.00001) (hypomagnesemia vs. normal magnesium or hypermagnesemia) after multivariable adjusted. On the contrary, hypermagnesemia was inversely associated with all-cause mortality in patients with CKD and ESRD (HR 0.86; 95% CI 0.79-0.94; p = 0.001) (per unit increase). Moreover, a significant association between hypermagnesemia and decreased risk of cardiovascular mortality was observed (HR 0.71; 95% CI 053-0.97, p = 0.03) in the adjusted model. In addition, subgroup analysis found that hypomagnesemia was strongly associated with increased all-cause mortality in hemodialysis patients (HR 1.29; 95% CI 1.12-1.50; p = 0.0005) (hypomagnesemia vs. normal magnesium or hypermagnesemia). CONCLUSIONS: Our results indicate that hypomagnesemia is significantly associated with cardiovascular and all-cause mortality in patients with CKD and ESRD. Further studies evaluating benefits of magnesium correction in CKD and dialysis patients with hypomagnesemia should be performed.
Authors: Marcello Tonelli; Natasha Wiebe; Bruce Culleton; Andrew House; Chris Rabbat; Mei Fok; Finlay McAlister; Amit X Garg Journal: J Am Soc Nephrol Date: 2006-05-31 Impact factor: 10.121
Authors: Yiqing Song; JoAnn E Manson; Nancy R Cook; Christine M Albert; Julie E Buring; Simin Liu Journal: Am J Cardiol Date: 2005-08-29 Impact factor: 2.778
Authors: Jun Sugimoto; Andrea M Romani; Alice M Valentin-Torres; Angel A Luciano; Christina M Ramirez Kitchen; Nicholas Funderburg; Sam Mesiano; Helene B Bernstein Journal: J Immunol Date: 2012-05-18 Impact factor: 5.422
Authors: Anastasia Markaki; John Kyriazis; Kostas Stylianou; George A Fragkiadakis; Kostas Perakis; Andrew N Margioris; Emmanuel S Ganotakis; Eugene Daphnis Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240
Authors: Akshay Varghese; Eduardo Lacson; Jessica M Sontrop; Rey R Acedillo; Ahmed A Al-Jaishi; Sierra Anderson; Amit Bagga; Katie L Bain; Laura L Bennett; Clara Bohm; Pierre A Brown; Christopher T Chan; Brenden Cote; Varun Dev; Bonnie Field; Claire Harris; Shasikara Kalatharan; Mercedeh Kiaii; Amber O Molnar; Matthew J Oliver; Malvinder S Parmar; Melissa Schorr; Nikhil Shah; Samuel A Silver; D Michael Smith; Manish M Sood; Irina St Louis; Karthik K Tennankore; Stephanie Thompson; Marcello Tonelli; Hans Vorster; Blair Waldvogel; James Zacharias; Amit X Garg Journal: Can J Kidney Health Dis Date: 2020-10-22
Authors: Rami Azem; Remy Daou; Elias Bassil; Eva Maria Anvari; Jonathan J Taliercio; Susana Arrigain; Jesse D Schold; Tushar Vachharajani; Joseph Nally; Georges N Na Khoul Journal: BMC Nephrol Date: 2020-02-12 Impact factor: 2.388
Authors: Cristian Rodelo-Haad; M Victoria Pendón-Ruiz de Mier; Juan Miguel Díaz-Tocados; Alejandro Martin-Malo; Rafael Santamaria; Juan Rafael Muñoz-Castañeda; Mariano Rodríguez Journal: Front Cell Dev Biol Date: 2020-11-12